Fundraising and Board Strengthening Gains Momentum in Preparations for Launch of IDE Pivotal Trial
Aachen, Germany, March 26, 2024–(BUSINESS WIRE)–Protenvis GmbH (Protenvis), a privately held cardiovascular medical device company, today announced a $3,000 Series B financing round to support registration of the PROTEMBO Investigational Device Exemption (IDE). announced the completion of 1 million euros. Critical Trial (NCT05873816). This funding round consists of his two separate capital increases, both of which have been completed. The project was co-led by a European consortium of his VC investors including Sweden-based Segulah Medical Acceleration, Italy-based XGEN Venture and Germany-based TechVision Fund. Other investors include Coparion, several large family offices, angel investors and a multinational medical device strategy firm.
Karl von Mangold and Konrad Rasmus, co-CEOs of Protenbis, said: “We are pleased to announce the completion of this round and would like to thank existing and new investors for their support. I would like to thank you for your trust.” “This means the field of cerebral embolism prevention is booming, with future growth driven by younger, lower-risk patients who are willing to accept no risk of brain injury when choosing to undergo transcatheter aortic valve replacement. It reflects the fact that
Additionally, Protenbis is proud to announce that Keith D. Dawkins, MD, has joined the company's Board of Directors. Dr. Dawkins has over 35 years of experience in the cardiovascular setting. He has worked as an interventional cardiologist in the UK for over 20 years, held a research role as a Fulbright Scholar at Stanford University, served as President of the British Interventional Cardiovascular Association, and has published over 750 academic publications and presentations. I wrote it. Dr. Dawkins has served as Chief Medical Officer (CMO) of Shockwave (NASDAQ:SWAV) since 2019. Prior to this, he held a senior position as global CMO at Boston Scientific, Inc. since 2008. He also serves on the boards of Ventric Health LLC and his JenaValve Technology Inc., and as chairman of his InnovHeart srl, Dr. Dawkins will contribute his significant expertise to Protenbis' clinical strategy and as the IDE study reaches its conclusion. Will contribute to pre-commercial programs.
“The addition of a visionary leader like Dr. Dawkins to our Board of Directors is an exciting sign that cerebral embolism prevention represents a significant opportunity for the future of transcatheter therapy. We look forward to working closely with them as they evolve and our superiority trials gain momentum.'' Dr. Ajin Parkhizgar, Chairman of the Board, said:
“As a long-time believer in the need to protect the brain from new lesions during transcatheter aortic valve replacement, I am excited to join Protenbis,” said Dr. Dawkins. “We believe that both the ProtEmbo system and the clinical trial design are novel and will have a major disruptive impact on the field of embolic prevention, eliminating or reducing many of the current concerns of the medical community. I am.”
About ProtEmbo® and Protenbis
pro embo® The Cerebral Protection System is an intra-aortic filter device that protects the entire brain from embolic material released during transcatheter aortic valve replacement (TAVR). It is a low-profile, non-thrombogenic system that protects all cerebral vessels and is delivered through the left radial artery for optimal placement and stability. This is an ideal access site where the physician can avoid interference with her TAVR device, which is typically delivered through the femoral artery.
Protembis is a privately-held startup medical device company that developed ProtEmbo.® Brain protection system. The company is developing a simple, reliable product that protects patients from brain injury during left heart heart surgery, improves patient quality of life, and reduces overall medical costs associated with brain injury during such surgeries. We are committed to providing solutions. The ProtEmbo system is currently under clinical study.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240325053798/ja/
contact address
Protenbis
Konrad Rasmus & Karl von Mangold
+49(0)241 9903 3622
Management@protembis.com
www.protembis.com
